Janus Henderson Group PLC Has $57,000 Holdings in Perspective Therapeutics, Inc. (NYSE:CATX)

Janus Henderson Group PLC decreased its position in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 99.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 17,839 shares of the company's stock after selling 4,781,513 shares during the period. Janus Henderson Group PLC's holdings in Perspective Therapeutics were worth $57,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its stake in Perspective Therapeutics by 7.4% during the fourth quarter. BNP Paribas Financial Markets now owns 51,094 shares of the company's stock valued at $163,000 after purchasing an additional 3,529 shares during the last quarter. Rhumbline Advisers lifted its stake in Perspective Therapeutics by 4.5% during the fourth quarter. Rhumbline Advisers now owns 94,992 shares of the company's stock valued at $303,000 after purchasing an additional 4,075 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Perspective Therapeutics by 3.4% during the fourth quarter. Bank of New York Mellon Corp now owns 143,469 shares of the company's stock valued at $458,000 after purchasing an additional 4,693 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Perspective Therapeutics by 24.1% during the third quarter. JPMorgan Chase & Co. now owns 24,912 shares of the company's stock valued at $333,000 after purchasing an additional 4,844 shares during the last quarter. Finally, Nicholson Wealth Management Group LLC lifted its stake in Perspective Therapeutics by 0.4% during the fourth quarter. Nicholson Wealth Management Group LLC now owns 1,609,283 shares of the company's stock valued at $5,134,000 after purchasing an additional 7,000 shares during the last quarter. Institutional investors own 54.66% of the company's stock.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, CEO Johan M. Spoor purchased 22,026 shares of the company's stock in a transaction dated Friday, March 28th. The shares were bought at an average price of $2.24 per share, for a total transaction of $49,338.24. Following the purchase, the chief executive officer now directly owns 59,383 shares in the company, valued at $133,017.92. This trade represents a 58.96% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert F. Williamson III purchased 22,192 shares of the company's stock in a transaction dated Friday, March 28th. The shares were acquired at an average price of $2.27 per share, for a total transaction of $50,375.84. Following the purchase, the director now owns 70,837 shares in the company, valued at $160,799.99. The trade was a 45.62% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 115,696 shares of company stock worth $256,344 in the last 90 days. 3.52% of the stock is owned by insiders.

Perspective Therapeutics Stock Up 7.5%

CATX stock traded up $0.18 during midday trading on Wednesday, reaching $2.58. The company had a trading volume of 906,847 shares, compared to its average volume of 1,036,024. Perspective Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $16.55. The company has a 50 day moving average of $2.24 and a two-hundred day moving average of $3.19.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on CATX shares. Truist Financial reduced their price target on shares of Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Tuesday, March 4th. Wedbush restated an "outperform" rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, May 13th. Lifesci Capital upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Thursday, March 6th. Finally, HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Perspective Therapeutics in a research report on Monday, March 31st. One research analyst has rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $12.50.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.